本帖最后由 老马 于 2013-3-13 13:43 编辑
" f: c% |4 ^& w, J p; l% [. T7 |/ V7 d2 U
健择(吉西他滨)+顺铂+阿瓦斯汀
. u. M3 m1 H- y' H6 ~8 H4 M Gemzar +Cisplatin + Avastin
( \- f/ M0 S& A0 O9 M; D% ^9 D3 Ohttp://annonc.oxfordjournals.org/content/21/9/1804.full
, Q E5 X5 ?0 G2 J6 a9 c( s* aOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 E8 F) t: l0 J6 R: N' XPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 }. v3 E2 u. V S1 tResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% Z$ z. d% a* M6 Z5 L
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 233)
/ R& S3 ~/ N4 e: g- H
华为网盘附件:
% c- y5 Z( M5 L9 j. K# u【华为网盘】ava.JPG
! N' ^8 ~7 K' D5 J |